|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
Network CGA: Comprehensive molecular
portraits of human breast tumours. Nature. 490:61–70. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Perou CM, Sorlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sorlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Sotiriou C and Piccart MJ: Taking
gene-expression profiling to the clinic: when will molecular
signatures become relevant to patient care? Nat Rev Cancer.
7:545–553. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Slamon DJ, Godolphin W, Jones LA, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Romond EH, Perez EA, Bryant J, et al:
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive
breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Slamon DJ, Leyland-Jones B, Shak S, et al:
Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Vogel CL, Cobleigh MA, Tripathy D, et al:
Efficacy and safety of trastuzumab as a single agent in first-line
treatment of HER2-overexpressing metastatic breast cancer. J Clin
Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Lan KH, Lu CH and Yu D: Mechanisms of
trastuzumab resistance and their clinical implications. Ann NY Acad
Sci. 1059:70–75. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Zhang S, Huang WC, Li P, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Nahta R, Yu D, Hung MC, Hortobagyi GN and
Esteva FJ: Mechanisms of disease: understanding resistance to
HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol.
3:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Berns K, Horlings HM, Hennessy BT, et al:
A functional genetic approach identifies the PI3K pathway as a
major determinant of trastuzumab resistance in breast cancer.
Cancer Cell. 12:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Di Cristofano A and Pandolfi PP: The
multiple roles of PTEN in tumor suppression. Cell. 100:387–390.
2000.PubMed/NCBI
|
|
17.
|
Hollander MC, Blumenthal GM and Dennis PA:
PTEN loss in the continuum of common cancers, rare syndromes and
mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Esteva FJ, Guo H, Zhang S, et al: PTEN,
PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab
response and survival in patients with HER2-positive metastatic
breast cancer. Am J Pathol. 177:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Fujita T, Doihara H, Kawasaki K, et al:
PTEN activity could be a predictive marker of trastuzumab efficacy
in the treatment of ErbB2-overexpressing breast cancer. Br J
Cancer. 94:247–252. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Nagata Y, Lan KH, Zhou X, et al: PTEN
activation contributes to tumor inhibition by trastuzumab, and loss
of PTEN predicts trastuzumab resistance in patients. Cancer Cell.
6:117–127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Alvarez RH, Valero V and Hortobagyi GN:
Emerging targeted therapies for breast cancer. J Clin Oncol.
28:3366–3379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Wang Q, Li SH, Wang H, et al: Concomitant
targeting of tumor cells and induction of T-cell response
synergizes to effectively inhibit trastuzumab-resistant breast
cancer. Cancer Res. 72:4417–4428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Andrechek ER, Hardy WR, Siegel PM,
Rudnicki MA, Cardiff RD and Muller WJ: Amplification of the
neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc
Natl Acad Sci USA. 97:3444–3449. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Dourdin N, Schade B, Lesurf R, et al:
Phosphatase and tensin homologue deleted on chromosome 10
deficiency accelerates tumor induction in a mouse model of ErbB-2
mammary tumorigenesis. Cancer Res. 68:2122–2131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Ursini-Siegel J, Rajput AB, Lu H, et al:
Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary
tumor development. Mol Cell Biol. 27:6361–6371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Zhang H, Wang Q, Montone KT, et al: Shared
antigenic epitopes and pathobiological functions of
anti-p185(her2/neu) monoclonal antibodies. Exp Mol Pathol.
67:15–25. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Frese KK and Tuveson DA: Maximizing mouse
cancer models. Nat Rev Cancer. 7:645–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Vargo-Gogola T and Rosen JM: Modelling
breast cancer: one size does not fit all. Nat Rev Cancer.
7:659–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Gopinathan A and Tuveson DA: The use of
GEM models for experimental cancer therapeutics. Dis Model Mech.
1:83–86. 2008. View Article : Google Scholar
|
|
30.
|
Schade B, Rao T, Dourdin N, et al: PTEN
deficiency in a luminal ErbB-2 mouse model results in dramatic
acceleration of mammary tumorigenesis and metastasis. J Biol Chem.
284:19018–19026. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Mittelman A, Casper ES, Godwin TA, Cassidy
C and Young CW: Phase I study of tricyclic nucleoside phosphate.
Cancer Treat Rep. 67:159–162. 1983.PubMed/NCBI
|
|
32.
|
Hoffman K, Holmes FA, Fraschini G, et al:
Phase I-II study: triciribine (tricyclic nucleoside phosphate) for
metastatic breast cancer. Cancer Chemother Pharmacol. 37:254–258.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Garrett CR, Coppola D, Wenham RM, et al:
Phase I pharmacokinetic and pharmacodynamic study of triciribine
phosphate monohydrate, a small-molecule inhibitor of AKT
phosphorylation, in adult subjects with solid tumors containing
activated AKT. Invest New Drugs. 29:1381–1389. 2011. View Article : Google Scholar
|
|
34.
|
Evangelisti C, Ricci F, Tazzari P, et al:
Preclinical testing of the Akt inhibitor triciribine in T-cell
acute lymphoblastic leukemia. J Cell Physiol. 226:822–831. 2011.
View Article : Google Scholar
|
|
35.
|
Lu CH, Wyszomierski SL, Tseng LM, et al:
Preclinical testing of clinically applicable strategies for
overcoming trastuzumab resistance caused by PTEN deficiency. Clin
Cancer Res. 13:5883–5888. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Balasis ME, Forinash KD, Chen YA, et al:
Combination of farnesyltransferase and Akt inhibitors is
synergistic in breast cancer cells and causes significant breast
tumor regression in ErbB2 transgenic mice. Clin Cancer Res.
17:2852–2862. 2011. View Article : Google Scholar
|
|
37.
|
Dieterle A, Orth R, Daubrawa M, et al: The
Akt inhibitor triciribine sensitizes prostate carcinoma cells to
TRAIL-induced apoptosis. Int J Cancer. 125:932–941. 2009.
View Article : Google Scholar
|
|
38.
|
Voskoglou-Nomikos T, Pater JL and Seymour
L: Clinical predictive value of the in vitro cell line, human
xenograft, and mouse allograft preclinical cancer models. Clin
Cancer Res. 9:4227–4239. 2003.PubMed/NCBI
|
|
39.
|
Park S, Jiang Z, Mortenson ED, et al: The
therapeutic effect of anti-HER2neu antibody depends on both innate
and adaptive immunity. Cancer Cell. 18:160–170. 2010. View Article : Google Scholar
|
|
40.
|
Ferris RL, Jaffee EM and Ferrone S: Tumor
antigen-targeted, monoclonal antibody-based immunotherapy: clinical
response, cellular immunity, and immunoescape. J Clin Oncol.
28:4390–4399. 2010. View Article : Google Scholar
|
